USPTO serial 86701347
DIMENSION THERAPEUTICS
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- POLLACK, ALISON FRIEDBERG
- Law office
- TMEG LAW OFFICE 106 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DIMENSION THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Eleanor M. Yost
Eleanor M. Yost Goodwin Procter LLP901 New York Avenue NWAttn: Trademark AdministratorWashington, DC 20001-4432Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, all for in-vivo use in gene therapy; chemical products, reagents, and biomolecules used for scientific and medical purposes | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of genetic diseases and disorders; Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, dermatological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, hematologic, and fungal and viral diseases and disorders; pharmaceutical preparations for the treatment of cancer, pain, diabetes, damaged skin, damaged tissue and addiction; Gene therapy and prophylaxis products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders; Gene therapy and phrophylaxis products for the treatment of liver, hepatological, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, dermatological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, hematologic, fungal and viral diseases and disorders | ACTIVE | — |
| 042 | Biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; development of products being genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; and companion diagnostics and assays services in the field of gene therapy design and delivery | ACTIVE | — |
| 044 | Providing medical services, namely, gene therapy design and delivery services in the field of genetic diseases and disorders, providing medical services, namely, gene therapy design and delivery services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, dermatological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, hematologic, fungal and viral diseases and disorders; and pharmaceutical preparations for the treatment of cancer, pain, diabetes, damaged skin, damaged tissue and addiction | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 16, 2017 | MAB1 | ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT | — |
| May 16, 2017 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| May 15, 2017 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Nov 14, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 14, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 14, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 21, 2016 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Oct 18, 2016 | ALIE | ASSIGNED TO LIE | — |
| Apr 1, 2016 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 1, 2016 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 1, 2016 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 31, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 31, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 24, 2015 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 24, 2015 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 3, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 2, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 29, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 25, 2015 | NWAP | NEW APPLICATION ENTERED | — |